Hasan GÖĞEBAKAN,
Gözde YILDIRIM ÇETİN
The effect of anti TNF alpha (certolizumab) treatment on insulin resistance, lipid parameters and cardiovascular risk in patients with axial spondyloarthritis (ankylosing spondylitis)
The effect of anti TNF alpha (certolizumab) treatment on insulin resistance, lipid parameters and cardiovascular risk in patients with axial spondyloarthritis (ankylosing spondylitis)
DAHUDER Medical Journal
2022-Cilt: 2 - Sayı: 3
65-72
Ankylosing spondylitis,
Certolizumab,
İnsulin resistance,
Framingham risk scoring,
Lipid parameters.,
Ankylosing spondylitis,
Certolizumab,
İnsulin resistance,
Framingham risk scoring,
Lipid parameters.
10624